- Home
- RAND vs NRXS Comparison
RAND vs NRXS Comparison
Compare RAND & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RAND | NRXS |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 49.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RAND | NRXS |
|---|---|---|
| Price | $11.28 | $4.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 8.8K | ★ 151.4K |
| Earning Date | 03-09-2026 | 11-10-2025 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $10.56 | $1.33 |
| 52 Week High | $31.89 | $6.20 |
Technical Indicators
Market Signals| Indicator | RAND | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 64.62 |
| Support Level | $11.23 | $4.33 |
| Resistance Level | $12.50 | $5.05 |
| Average True Range (ATR) | 0.42 | 0.32 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 13.70 | 67.82 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).